GlobeNewswire

World Conference on Lung Cancer Wednesday Press Conference: Applying Conference Discoveries and Themes to the Real World

Del

TORONTO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- The final press briefing from the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC) was led by conference co-presidents Natasha B. Leighl, M.D., BSc, MSc, and Gail Darling M.D., FRCSC, who reviewed the innovative work in lung cancer research and treatment presented over the course of the conference. “The future is bright, and I think we’ve seen that at this conference,” said Dr. Darling.

Paul A. Bunn Jr., M.D., distinguished professor, Division of Medical Oncology at the University of Colorado, provided an experienced practitioner’s view on the impact of this year’s practice-changing abstracts. Emphasizing that lung cancer is the leading cause of cancer deaths in the world and in men and women, Dr. Bunn said that the best thing to do is prevent it and to find it early. In commenting on the impact of “overwhelming” improvement in lung cancer mortality seen in the NELSON trial on randomized CT screenings, Dr. Bunn stated, “Even more than a coloscopy or a mammography, women in the world at risk for lung cancer should undergo an annual CT screening.”

Jill Feldman, lung cancer survivor and advocate, lost both parents, an aunt and a grandparent to lung cancer and shared her drive to advocate for an increase in research and treatment of this devastating disease. “When I look at these practice-changing abstracts, I know they’re exciting for clinicians, but for patients, they’re life changing,” Feldman said. “We must keep forging ahead, so others have the chance to watch their children grow up.”

Anna Farago, M.D., Ph.D., medical oncologist at Mass General Hospital, provided a young practitioner’s perspective on the practice-changing abstracts. In discussing the impact of the PACIFIC trial, Dr. Farago stated, “Based on the overall survival data we saw from the this trial presented at the WCLC, I think durvalumab is now solidified as the standard of care for Stage III unresectable non-small cell lung cancer following chemotherapy and radiation.”

In commenting on the IMpower133 trial, Dr. Farago concluded, “The standard of care/first line therapy for small cell lung cancer has been unchanged for 30 years. This is the first trial to demonstrate a clinically significant survival benefit.” 

Study analyzes use of thoracic radiotherapy for limited-stage SCLC
A recent study led by Xiao Hu, M.D., Ph.D., Department of Thoracic Radiotherapy, Zhejiang Cancer Hospital, demonstrated that using involved field radiotherapy (IFRT) and irradiating post-chemotherapy residual primary tumor volume for limited-stage small cell lung cancer (SCLC) did not result in increased recurrence of the cancer.

While combined chemotherapy and thoracic radiotherapy (TRT) is the standard of care for most patients with SCLC, TRT target volumes of limited-stage SCLC have been controversial. To date, this is the only prospective randomized study on these issues evaluating TRT for limited-stage SCLC.

“Considering the high malignancy and easy metastasis of SCLC, chemotherapy remains the cornerstone of comprehensive treatment,” said Dr. Hu. “For patients having difficulty with full-dose intravenous chemotherapy, it could be administered safely by dose reduction or using single agent chemotherapy or oral chemotherapy, along with radiotherapy.”

Read the full press release here.

Dr. Leighl closed the press briefing with a preview of today’s closing plenary, “The goal of this plenary is to help us take the great progress at this meeting—take it home, take action and really put this into practice.” 

Livestreams of the daily press conferences are available here.

About the WCLC
The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated solely to lung cancer and other thoracic malignancies, attracting over 7,000 researchers, physicians and specialists from more than 100 countries. The conference will cover a wide range of disciplines and unveil research studies and clinical trial results. For more information, visit http://wclc2018.iaslc.org/. Follow the conference on social media with: #WCLC2018.

About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. You can also follow the IASLC on Twitter, Facebook, LinkedIn and Instagram.

Contacts:
Lisa Rivero
Vice President
lrivero@jpa.com | +1 617-657-1305
Becky Bunn, MSc
Public Relations Manager
Becky.Bunn@IASLC.org | +1 720-254-9509

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

ADC Therapeutics and Adagene Announce License Agreement24.4.2019 07:00:00 CESTPressemelding

ADC Therapeutics to develop next-generation masked antibody drug conjugates (ADCs), incorporating Adagene’s SAFEbody ™ technology, with potential utility across multiple tumor types Collaboration enables focus on targets in which healthy tissue expression precludes development of ADCs incorporating traditional antibodies LAUSANNE, Switzerland and SUZHOU, China, April 24, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), and Adagene Inc., an antibody engineering and discovery company, today announced that they have entered into a discovery collaboration and license agreement. ADC Therapeutics will use Adagene’s SAFEbody™ technology to generate a masked antibody that will be combined with ADC Therapeutics’ pyrrolobenzodiazepine (PBD) cytotoxic payload technology for the development of a novel ADC against a solid tumor target. Adagene has developed the SAFEbody t

Media Advisory: Bombardier to Report its First Quarter 2019 Financial Results and to Hold its Annual Meeting of Shareholders on Thursday, May 223.4.2019 22:54:00 CESTPressemelding

MONTRÉAL, April 23, 2019 (GLOBE NEWSWIRE) -- Bombardier (TSX: BBD.B) will publish its financial results for the first quarter of 2019 and hold its annual meeting of shareholders at the Grand Quay (former Alexandra Pier) located in Montréal’s Old Port on Thursday, May 2, 2019. Quarterly conference call On May 2 at 8:00 a.m., EDT, Bombardier’s management will hold a webcast/conference call intended for investors and financial analysts to review the company’s financial results for the first quarter of 2019. Please find below the dial-in information for the call: In English: 514 394 9320 or 1 866 240 8954 (toll-free in North America) +800 6578 9868 (overseas calls) In French: 514 394 9316 or (with translation) 1 888 791 1368 (toll-free in North America) +800 6578 9868 (overseas calls) Annual meeting of shareholders WHERE: Grand Quay, 200 de la Commune Street West, Montréal, Québec, H2Y 4B2 WHEN: Thursday, May 2, 2019 Media registration: 9:30 a.m. - 10:15 a.m. Eastern Daylight Time (EDT) Op

Patton Enhances Cloud Orchestration Service with OA&M Messaging23.4.2019 20:05:00 CESTPressemelding

Expanding its virtualized NMS with alerts and notifications sent to mobile teams, Patton reduces operational expense and complexity for service providers SmartNode VoIP… More than Just Talk! GAITHERSBURG, Md., April 23, 2019 (GLOBE NEWSWIRE) -- Patton Electronics—creator of SmartNode virtual VoIP CPE and CopperLink Ethernet and power-over-Ethernet extenders—has enhanced its revolutionary Patton Cloud virtualized edge-orchestration service by adding new alerts and notifications capabilities, the company announced today. WATCH the VIDEO TUTORIAL Patton Cloud Alerts and Notifications Added alerting and notification capabilities augment the Patton Cloud with fault and performance-monitoring tools for service-quality assurance, as well as device and service management. The Patton cloud already provides automated onboarding and provisioning as part of its full-service, life-cycle orchestration solution. Now, element status, statistics, faults, alerts, and alarms can all be delivered to techn

Continued Growth for INVNT Following Client Wins, An Expanded Offering, New Offices and Fresh Talent23.4.2019 15:20:00 CESTPressemelding

NEW YORK, NY, April 23, 2019 (GLOBE NEWSWIRE) -- INVNT, the global live brand storytelling agency™, achieved a number of milestones in 2018, a move that saw its revenues reach over $54 million, exceeding forecasts and representing a 30% increase on the previous year. With a number of impressive new clients and continued expansion in the works, the agency is targeting $62 million in revenue for 2019. INVNT secured new clients including Microsoft, Facebook, Pfizer, Xero, TEDxSydney, New Relic and Mary Kay last year. They grew many accounts from local to global, a move that now sees INVNTrs deliver campaigns for clients across the globe. INVNT also exceeded existing clients’ expectations in 2018, delivering compelling live brand storytelling™ moments for the likes of General Motors, Grant Thornton, Merck, PepsiCo, Samsung and Subway. Scott Cullather, CEO, INVNT explains: “Our tremendous growth is due to a combination of our team’s ability to develop compelling live brand stories that are

Always Powered by Passion: Meizu 16s Flagship Smartphone Unveiled, Snapdragon 855 and 48MP OIS Dual Camera23.4.2019 15:00:00 CESTPressemelding

Zhuhai, April 23, 2019 (GLOBE NEWSWIRE) -- Zhuhai, 23rd April 2019 -- Meizu Technology Co., Ltd (Meizu) has officially introduced its latest flagship 16s and will be available for sale in China on 28th April starting at 3198 RMB. The signature Meizu Design brings a sense of elegance to the phone. Powered by Qualcomm Snapdragon 855, the 16s features a 48MP + OIS Dual Camera, making it the best device to use for everyday shots. The latest flagship 16s is a testament to the 16 years’ experience in phone making of Meizu. The company has spared no effort with 100% dedication in producing premium phone for quality-seeking users, despite the size of the target market. 16s is a product that reflects ‘100% efforts for 1% selected Products’, Meizu strives for excellence with passion. Meizu 16s comes in Pearl White, Carbon Black, and Phantom Blue, of which 6+128G, 8+128G and 8+256G will be respectively priced at 3198 RMB, 3498 RMB and 3998 RMB, and will be available on Meizu official website for

iGrafx Announces Cohesive RPA Accelerator Solution23.4.2019 14:48:00 CESTPressemelding

Combines Core Capabilities from iGrafx, myInvenio, Servicetrace, UiPath and BP3 Global Dallas, TX, April 23, 2019 (GLOBE NEWSWIRE) -- Today at the iNNOVATE 2019 conference, iGrafx unveiled the industry’s first end-to-end RPA Accelerator solution, enabling enterprises to identify, assess, prioritize, execute and govern robotic process automation (RPA) projects. The turnkey package includes a new version of the iGrafx Platform, along with process mining from myInvenio, RPA bots from either UiPath or Servicetrace and professional services from BP3. For the first time ever, Center of Excellence leaders can access the combined, best-of-breed capabilities from a single source for a single price. “Our customers tell us that they have a huge challenge understanding what to optimize and automate in order to achieve real digital transformation,” said Ryan Tognazzini, CEO at iGrafx. This is a challenge that is also iterated again and again by industry experts. In a recent Forrester report, Rob Ko